Furui Co.,Ltd(300049) Shenwan Hongyuan Securities·2025-06-03 13:49Investment Rating - The report initiates coverage with a "Buy" rating for the company [2][8]. Core Views - The company is positioned as a "water seller" in the MASH (Metabolic Associated Steatotic Hepatitis) market, with significant growth potential expected in the coming years [7][8]. - The company has a comprehensive product portfolio that includes pharmaceuticals, diagnostic equipment, and medical services, focusing on liver health management [7][18]. - The demand for liver disease screening is anticipated to surge due to the emergence of new MASH drugs and the establishment of screening protocols in medical institutions [7][8]. Summary by Sections 1. Focus on Liver Disease - The company has over 20 years of experience in the liver disease sector and has actively pursued overseas acquisitions and global expansion [18]. - It offers a complete product/service combination of drugs (notably the patented Fufang Bie Jia Ruan Gan Pian), diagnostic devices (FibroScan series), and medical services [20][21][22]. 2. FibroScan and Market Potential - FibroScan is recognized as a leading diagnostic tool in the liver disease field, with over 5,200 clinical research publications supporting its efficacy [7][21][67]. - The global prevalence of liver diseases, particularly MASH, is significant, with early diagnosis being crucial for reversing liver fibrosis [43][44]. - The report highlights the rapid progress of MASH drug development, with several drugs expected to be approved soon, which will likely increase the demand for liver screening [54][60]. 3. Financial Projections - Revenue projections for the company are set at 16.77 billion yuan, 20.63 billion yuan, and 25.06 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 24.3%, 23.0%, and 21.4% [6][8]. - The net profit attributable to the parent company is expected to reach 2.21 billion yuan, 3.14 billion yuan, and 4.29 billion yuan for the same years, with growth rates of 95.5%, 41.6%, and 36.9% [6][8]. 4. Competitive Landscape and Market Strategy - The company is well-positioned in the academic field of liver disease diagnostics and has established a strong customer base in both domestic and international markets [7][8]. - The introduction of a pay-per-use model for FibroScan devices is expected to enhance market penetration, particularly in primary healthcare settings [36][70]. 5. Valuation - The company's reasonable market capitalization is estimated at 14 billion yuan, indicating a potential upside of approximately 48% relative to its market value as of May 30, 2025 [8].